GASTROINTESTINAL DISORDERS—Cost Studies

PGI4 BUDGET IMPACT OF METHYLNALTREXONE SC ON A PUBLIC DRUG PROGRAM FORMULARY
Wang M1, Iyer S2, Jedd M3
1Wyeth Pharmaceuticals, Markham, ON, Canada, 2Wyeth Pharmaceuticals, Collegville, PA, USA, 3Innomar Strategies Inc, Burlington, ON, Canada

OBJECTIVES: To estimate the financial impact to the Ontario Public Drug Programs (OPDP) for providing coverage for methylnaltrxone subcutaneous injection (RELISTOR®) for the treatment of Opioid Induced Constipation (OIC) in patients with advanced illness, receiving palliative care when response to laxatives has been insufficient. METHODS: A population-based model was developed to estimate the annual financial impact of adding methylnaltrxone to the OPDP drug formulary. Attrition factors were applied in a stepwise approach starting with the population of Ontario in order to forecast the number of palliative patients expected to use methylnaltrxone following its addition to the drug formulary. Targeted treatment population in the analysis is limited to patients meeting the product monograph indication/criteria. Only drug costs incurred by the OPDP are included. No discounting or inflation were applied. Data sources included literature sources, publicly available population statistics, and market research. RESULTS: This analysis estimates that funding methylnaltrxone, per product monograph indication, in the province of Ontario would lead to an incremental drug reimbursement cost of $1,754,265, $3,942,857, and $5,563,842 in Year 1, 2, and 3 respectively post listing. The total cumulative impact, post listing over the three-year period is expected to be $11.26 million. Pessimistic and optimistic scenarios were evaluated in the sensitivity analysis to provide a range of costs to the drug plan budget. The estimated impact over a three-year period will be an incremental cost of $6.65 million and $17.46 million for pessimistic and optimistic scenario respectively. CONCLUSIONS: Addition of methylnaltrxone will provide patients and care providers with a therapeutic option to rapidly and reliably improve patient well-being at the end of life while having a modest impact on the OPDP drug budget.

PGI5 A BUDGET IMPACT ANALYSIS FOR DETERMINING THE COSTS OF INCREASED PANTOPRAZOL IV PRESCRIPTION FOR THE MANAGEMENT OF PEPTIC ULCER IN SPAIN
Darba J1, Restovic G2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain

OBJECTIVES: A budget impact model was developed in order to estimate the economic impact of increased pantoprazole intravenous prescription in the management of Peptic Ulcer (PU) in Spain. METHODS: The analytic model is based on data from disease prevalence, population growth, drug consumption, ex-factory prices and market shares forecasts for the Spanish market. It takes the perspective of the Spanish National Health Care System and time horizon considered is 5 years. Annual discount rate was set at 5%. Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of gastro oesophageal reflux disease (GERD) and drugs considered in the study were omeprazole,esomeprazole and pantoprazole. The model estimates the annual cost to treat patients with GERD before and after the replacement by intravenous pantoprazole IV in the management of the disease in the Spanish setting. Annual costs consist of pharmacologic treatments, laboratory and diagnostic tests, specialist consultations, hospitalizations, transfusions, endoscopic treatments and surgical interventions. All costs are referred to 2007. RESULTS: It has been estimated that target population with PPIs treatments for GERD in Spain would be around 79,372 inhabitants in year 2007, arriving at 82,849 in 2012 due to Spanish population growth. Total cost for the next 5 years for the treatment of GERD with intravenous PPIs was estimated at €1224 million before the substitution and at €1200 million after the substitution. Mean cost per patient was estimated at €2513 before the replacement by intravenous pantoprazole and at €2464 after its substitution. CONCLUSIONS: This budget impact analysis estimates that increased pantoprazole intravenous prescription for the treatment of GERD in Spain is likely to represent a net savings of €24 millions in the Spanish National Health Care System in the next 5 years.

PGI6 THE MANAGEMENT OF GASTRO OESOPHAGEAL REFLUX DISEASE IN SPAIN: A BUDGET IMPACT ANALYSIS TO ESTIMATE COSTS DUE TO A GREATER PANTOPRAZOL IV PENETRATION
Darba J1, Restovic G2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research SL, Barcelona, Spain

OBJECTIVES: To estimate the economic impact for the health care system due to the substitution of intravenous omeprazole and intravenous esomeprazole by intravenous pantoprazole in the treatment of gastro oesophageal reflux disease in Spain. METHODS: A budget impact model was developed. The analytic model was based on data from disease prevalence, population growth, drug consumption, ex-factory prices and market shares forecasts for Spain. It takes the perspective of the Spanish National Health Care System and time horizon considered is five years. Annual discount rate was set at 5%. Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of gastro oesophageal reflux disease (GERD) and drugs considered in the study were omeprazole,esomeprazole and pantoprazole. The model estimates the annual cost to treat patients with GERD before and after the substitution by intravenous pantoprazole IV in the management of the disease in the Spanish setting. Annual costs consist of pharmacologic treatments, laboratory and diagnostic tests, specialist consultations, hospitalizations, transfusions, endoscopic treatments and surgical interventions. All costs are referred to 2007. RESULTS: It has been estimated that target population with PPIs treatments for GERD in Spain would be around 79,372 inhabitants in year 2007, arriving at 82,849 in 2012 due to Spanish population growth. Total cost for the next 5 years for the treatment of GERD with intravenous PPIs was estimated at €1224 million before the substitution and at €1200 million after the substitution. Mean cost per patient was estimated at €2513 before the replacement by intravenous pantoprazole and at €2464 after its substitution. CONCLUSIONS: This budget impact analysis estimates that increased pantoprazole intravenous prescription for the treatment of GERD in Spain is likely to represent a net savings of €24 millions in the Spanish National Health Care System in the next 5 years.

PGI7 AN ECONOMIC EVALUATION OF THE TWO LEADING ALGINTE THERAPIES IN THE UK: RESULTS FROM A LARGE LONGITUDINAL DATABASE
Connolly M1, Bhatt A2
1Global Market Access Solutions, St Prex, Switzerland, 2Reckitt Benkiser (Healthcare), Hull, UK

OBJECTIVES: Alginites are often first line therapy for patients experiencing symptoms of gastro-oesophageal reflux (GORD).